/COO
COO Stock - The Cooper Companies, Inc.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$82.75+0.35%
+$0.29 (+0.35%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.81
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).64
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+7.2%upside
Target: $88.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$81.92 – $83.58
TARGET (TP)$88.67
STOP LOSS$76.13
RISK/REWARD1:0.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.05
52W High$100.24
52W Low$61.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.09B | $3.90B | $3.59B | $3.31B | $2.92B |
| Gross Profit | $2.48B | $2.60B | $2.36B | $2.14B | $1.96B |
| Gross Margin | 60.7% | 66.6% | 65.6% | 64.7% | 66.9% |
| Operating Income | $682.90M | $705.70M | $533.10M | $507.60M | $505.80M |
| Net Income | $374.90M | $392.30M | $294.20M | $385.80M | $2.94B |
| Net Margin | 9.2% | 10.1% | 8.2% | 11.7% | 100.8% |
| EPS | $1.87 | $1.97 | $1.49 | $1.96 | $59.73 |
Company Overview
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
50%
Hold / Neutral
7
44%
Sell / Underperform
1
6%
Analyst Consensus🟡 Mixed
8 Bullish8 Neutral/Bearish
Price Targets
$201
Average Target
↑ 142.9% Upside
Now
$64
Low
$201
Average
$410
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Wells Fargo | Downgrade | Equal Weight | $72 |
| October 13th 2025 | Barclays | Initiation | Overweight | $85 |
| October 1st 2025 | Goldman | Initiation | Sell | $64 |
| August 28th 2025 | Citigroup | Downgrade | Neutral | $72 |
| July 22nd 2025 | BNP Paribas Exane | Upgrade | Outperform | $92 |
| June 17th 2025 | Needham | Upgrade | Buy | $94 |
| May 30th 2025 | JP Morgan | Downgrade | Neutral | $76 |
| August 29th 2024 | Piper Sandler | Reiterated | Overweight | $120← $115 |
| July 16th 2024 | Jefferies | Upgrade | Buy | $115← $107 |
| March 19th 2024 | Redburn Atlantic | Upgrade | Buy | $125 |
| March 13th 2024 | JP Morgan | Upgrade | Overweight | $120← $100 |
| February 6th 2024 | KeyBanc Capital Markets | Resumed | Sector Weight | - |
| October 30th 2023 | BofA Securities | Initiation | Buy | $380 |
| October 5th 2023 | Redburn Atlantic | Downgrade | Neutral | $343← $390 |
| May 30th 2023 | Morgan Stanley | Initiation | Equal Weight | $410 |
Earnings History & Surprises
COOBeat Rate
67%
Last 18 quarters
Avg Surprise
+1.8%
EPS vs Estimate
Beats / Misses
12/3
3 met exactly
Latest EPS
$1.15
Q4 2025
EPS Surprise History
Q1 24
+8.6%
$0.85vs$0.78
Q2 24
+2.5%
$0.85vs$0.83
Q3 24
+5.4%
$0.96vs$0.91
Q4 24
+4.0%
$1.04vs$1.00
Q1 25
+0.7%
$0.92vs$0.91
Q2 25
+3.4%
$0.96vs$0.93
Q3 25
+2.8%
$1.10vs$1.07
Q4 25
+3.6%
$1.15vs$1.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $1.02 | — | — | — |
Q4 2025 | Dec 4, 2025 | $1.11 | $1.15 | +3.6% | ✓ BEAT |
Q3 2025 | Aug 27, 2025 | $1.07 | $1.10 | +2.8% | ✓ BEAT |
Q2 2025 | May 29, 2025 | $0.93 | $0.96 | +3.4% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $0.91 | $0.92 | +0.7% | ✓ BEAT |
Q4 2024 | Dec 5, 2024 | $1.00 | $1.04 | +4.0% | ✓ BEAT |
Q3 2024 | Aug 28, 2024 | $0.91 | $0.96 | +5.4% | ✓ BEAT |
Q2 2024 | May 30, 2024 | $0.83 | $0.85 | +2.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.78 | $0.85 | +8.6% | ✓ BEAT |
Q4 2023 | Dec 7, 2023 | $0.87 | $0.87 | 0.0% | = MET |
Q3 2023 | Aug 30, 2023 | $0.84 | $0.84 | 0.0% | = MET |
Q2 2023 | Jun 1, 2023 | $0.75 | $0.77 | +2.7% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $0.67 | $0.73 | +9.0% | ✓ BEAT |
Q4 2022 | Dec 8, 2022 | $0.77 | $0.69 | -10.4% | ✗ MISS |
Q3 2022 | Aug 31, 2022 | $0.80 | $0.80 | 0.0% | = MET |
Q2 2022 | Jun 2, 2022 | $0.85 | $0.81 | -4.7% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $0.77 | $0.81 | +5.2% | ✓ BEAT |
Q4 2021 | Dec 2, 2021 | $0.84 | $0.82 | -2.4% | ✗ MISS |
Q3 2021 | Sep 2, 2021 | $0.83 | $0.85 | +2.4% | ✓ BEAT |
Latest News
Citigroup Maintains Neutral on Cooper Companies, Raises Price Target to $88
➖ NeutralBenzinga•Dec 8, 2025, 07:41 PM•Also:
Morgan Stanley Maintains Equal-Weight on Cooper Companies, Raises Price Target to $83
➖ NeutralBenzinga•Dec 8, 2025, 05:15 PM
Goldman Sachs Maintains Sell on Cooper Companies, Raises Price Target to $71
➖ NeutralBenzinga•Dec 8, 2025, 04:38 PM
Stifel Reiterates Buy on Cooper Companies, Raises Price Target to $95
📈 PositiveBenzinga•Dec 5, 2025, 05:32 PM•Also:
Piper Sandler Reiterates Overweight on Cooper Companies, Raises Price Target to $94
📈 PositiveBenzinga•Dec 5, 2025, 04:59 PM
Wells Fargo Maintains Equal-Weight on Cooper Companies, Raises Price Target to $82
📈 PositiveBenzinga•Dec 5, 2025, 04:16 PM
JP Morgan Maintains Neutral on Cooper Companies, Raises Price Target to $78
➖ NeutralBenzinga•Dec 5, 2025, 03:39 PM
Mizuho Maintains Outperform on Cooper Companies, Raises Price Target to $100
📈 PositiveBenzinga•Dec 5, 2025, 02:29 PM
Cooper companies shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 adjusted EPS guidance above estimates. Also, the company issued FY26 guidance above estimates.
📈 PositiveBenzinga•Dec 5, 2025, 01:50 PM
Baird Maintains Outperform on Cooper Companies, Raises Price Target to $98
📈 PositiveBenzinga•Dec 5, 2025, 12:47 PM
Needham Maintains Buy on Cooper Companies, Raises Price Target to $100
📈 PositiveBenzinga•Dec 5, 2025, 10:12 AM
Cooper Cos. jumps after starting strategic review, naming new board chair
📈 PositiveSeeking Alpha•Dec 4, 2025, 09:54 PM•Also:
Cooper companies shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 adjusted EPS guidance above estimates. Also, the company issued FY26 guidance above estimates.
📈 PositiveBenzinga•Dec 4, 2025, 09:25 PM
CooperCompanies Board Appoints Colleen Jay To Succeed Current Chair Robert Weiss, Effective January 2, 2026
➖ NeutralBenzinga•Dec 4, 2025, 09:23 PM
CooperCompanies Announces Formal Strategic Review
➖ NeutralBenzinga•Dec 4, 2025, 09:23 PM
Cooper Companies Sees FY2026 Adj EPS $4.45-$4.60 vs $4.09 Est; Sees Sales $4.299B-$4.338B vs $4.089B Est
📈 PositiveBenzinga•Dec 4, 2025, 09:16 PM
Cooper Companies Sees Q1 Adj EPS $1.02-$1.04 vs $1.00 Est; Sees Sales $1.019B-$1.030B vs $1.025B Est
📈 PositiveBenzinga•Dec 4, 2025, 09:16 PM
Cooper Companies Q4 Adj. EPS $1.15 Beats $1.11 Estimate, Sales $1.065B Beat $1.061B Estimate
📈 PositiveBenzinga•Dec 4, 2025, 09:15 PM
Wells Fargo Downgrades Cooper Companies to Equal-Weight, Maintains Price Target to $72
📉 NegativeBenzinga•Nov 13, 2025, 12:17 PM
Cooper Companies shares are trading higher after The Wall Street Journal reported that Jana Partners built a stake in the company and that Bausch + Lomb's CEO expressed interest in combining with Cooper's contact-lens unit.
📈 PositiveBenzinga•Oct 20, 2025, 11:44 AM•Also:
Frequently Asked Questions about COO
What is COO's current stock price?
The Cooper Companies, Inc. (COO) is currently trading at $82.75 per share. The stock has moved +0.35% today.
What is the analyst price target for COO?
The average analyst price target for COO is $88.67, based on 1 analyst.
What sector is The Cooper Companies, Inc. in?
The Cooper Companies, Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is COO's market cap?
The Cooper Companies, Inc. has a market capitalization of $16.48 billion, making it a large-cap company.
Does COO pay dividends?
No, The Cooper Companies, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDOCS
Doximity, Inc.
$43.65
Mkt Cap: $8.2B
FMS
Fresenius Medical Care AG & Co. KGaA
$23.51
Mkt Cap: $13.8B
HOLX
Hologic, Inc.
$74.95
Mkt Cap: $16.7B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
NBIX
Neurocrine Biosciences, Inc.
$145.00
Mkt Cap: $14.4B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
SOLV
Solventum Corporation
$81.59
Mkt Cap: $14.2B
TEM
Tempus AI, Inc.
$64.46
Mkt Cap: $11.1B
UHS
Universal Health Services, Inc.
$227.46
Mkt Cap: $14.7B
Explore stocks similar to COO for comparison